Szkodliwość antykoncepcji hormonalnej: piśmiennictwo

  1. Interna Szczeklika. Podręcznik chorob wewnętrznych 2014. Wyd. Medycyna Praktyczna; Krakow 2014.
  2. Zawilska K., Jaeschke R., Tomkowski W. i wsp.: Polskie wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Aktualizacja 2009. Aktualizacja 2012 Medycyna Praktyczna Ginekologia i Położnictwo 2009/05. http://www.mp.pl/artykuly/?aid=44289
  3. Kyrle P.A., Eichinger S.: Deep vein thrombosis. Lancet 2005 Mar 26–Apr 1; 365(9465):1163–74.
  4. Wu O., Robertson L., Langhorne P. et al.: Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005 Jul; 94(1):17–25.
  5. Martinez F., Avecilla A.: Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care 2007 Jun; 12(2):97–106.
  6. Van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P. et al.: The Venous Thrombotic Risk of Oral Contraceptives, Effects of Oestrogen Dose and Progestogen Type: Result of the MEGA Case-control Study. BMJ 2009; 339:b2921.
  7. Lidegaard O., Lokkegaard E., Svendsen A.L. et al.: Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339:b2890.
  8. Gerstman B.B., Piper J.M., Tomita D.K. et al.: Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133(1):32–37.
  9. Grzechocińska B.: Znaczenie dawki etynyloestradiolu w doustnej antykoncepcji. Nowa Medycyna. 2000; 8 http://www.czytelniamedyczna.pl/1423,znaczenie-dawki-etynyloestradiolu-w-doustnejantykoncepcji.html
  10. Gerstman B.B., Piper J.M., Tomita D.K. et al.: Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991 Jan; 133(1):32–7.
  11. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M. et al.: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995 Dec 16; 346(8990):1593–6.
  12. Vessey M., Mant D., Smith A. et al.: Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed) 1986 Feb 22; 292(6519):526.
  13. Kemmeren J.M., Algra A., Grobbe D.E.: Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001 Jul 21; 323(7305):131–4.
  14. Jick H., Jick S.S., Gurewich V. et al.: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995 Dec 16; 346(8990):1589–93.
  15. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995 Dec 16; 346(8990):1575–82.
  16. Bloemenkamp K.W., Rosendaal F.R., Buller H.R. et al.: Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999 Jan 11; 159(1):65–70.
  17. Speroff L., Philip D., Darney P.D.: Antykoncepcja vademecum. Wyd. Medycyna Praktyczna; Krakow 2014.
  18. Abdollahi M., Cushman M., Rosendaal F.R.: Obesity: risk of venous thrombosis and the interaction with coagulation factor levels end oral contraceptive use. Thromb Haemost 2003; 89(3):493–498.
  19. Nightingale A.L., Lawrenson R.A., Simpson E.L. et al.: The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5(4):265–74.
  20. Kumar V., Cotran R.S., Robbins S.: Patologia. Wyd. I pol. pod red. W.T. Olszewskiego. Urban & Partner; Wrocław 2005.
  21. Bloemenkamp K.W., Helmerhorst F.M., Rosendaal F.R. et al.: Thrombophilias and gynecology. Best Pract Res Clin Obstet Gynaecol 2003; 17(3):509–528.
  22. Emmerich J., Rosendaal F.R., Cattaneo M. et al.: Combined effects of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism – pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809–816.
  23. Vandenbroucke J.P., Koster T., Briet E. et al.: Increased risk of venous thrombosis in oral contraceptive users who are carriers of factors V Leiden mutation. Lancet 1994; 344(8935): 1453–1457.
  24. Legnani C., Palareti G., Guazzaloca G. et al.: Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002; 23(12):984–990.
  25. Blomenkamp K.W., Rosendaal F.R., Helmerhorst F.M. et al.: Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160:49–52.
  26. Parkin L., Skeeg D.C., Wilson M. et al.: Oral contraceptives and fatal pulmonary embolism. Lancet 2000; 355(9221):2133–2134.
  27. Dentali F., Crowther M., Ageno W.: Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood 2006; 107(7):2766–2773.
  28. de Bruijn S.F., Stam J., Koopman M.M.: Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and incorrection of who are carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998; 316(7131): 589–592.
  29. Lewis J., Tice H., Zimmerman H.: Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases. Dig Dis Sci 1983, 28, 673–683.
  30. Samborek M., Drosdzol A., Stojko R. et al.: Budd-Chiari syndrome induced by hormonal oral contraception in the patient with congenital thrombophilia – factor V Leiden mutation – a case report. Gin Pol 2008; 79:702–705.
  31. Valla D., Le M.G., Poynard T. et al.: Gastroenterology. Risk of hepatic vein thrombosis in relations to recent use of oral contraceptives. A case-control study 1986 Apr; 90(4):807–11.
  32. Maddrey W.C.: Hepatic vein thrombosis (Budd-Chiari syndrome): possible association with the use of oral contraceptives. Semin Liver Dis 1987 Feb; 7(1):32–9.
  33. Thygesen K., Alpert J.S., Jaffe A.S.: the Writing Group on behalf of the Joint ESC/ACCF/ AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myo-Anty_druk:Layout 1 2019-02-26 12:42 cardial infarction. European Heart Journal 2012; DOI: 10.1093/eurheartj/ehs 184, opracowano w Med. Prakt. 2012/10 http://kardiologia.mp.pl/wytyczne/show.html?id=76069
  34. Hodor J.: Epidemiologia chorob serca u kobiet. Puls Medycyny. 2006; 2(125) http://www.pulsmedycyny.com.pl/index/archiwum/6531,epidemiologia,chorob,serca.html
  35. Margolis K.L., Adami H.O., Luo J., Ye W., Weiderpass E.A.: prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007 Aug; 88(2):310–6.
  36. Lewis H.A., Heinemann L.A., Spitzer W.O. et al.: The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56(3):129–40.
  37. Sidney S., Petitti D.B., Quesenberry C.P. et al.: Myocardial infarction in users of low-dose oral contraceptives. Obstet. Gynecol. 1996; 88(6):939–44.
  38. Doring A., Frohlich M., Lowel H. et al.: Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004; 172(2):281–6.
  39. Paulus D., Saint-Remy A., Jeanjean M.: Oral contraception and cardiovascular risk factors during adolescence. Contraception 2000; 62(3):113–6.
  40. Rosendaal F.R., Helmerhorst F.M., Vandenbroucke J.P.: Female hormones and thrombosis. Arterioscler. Thromb Vasc. Biol. 2002; 22(2):201–10.
  41. Beigbeder J.Y., Klouche K., Gallay P. et al.: Myocardial infarction and anti-ethinylestradiol antibody. A propos of a case in an 18-year old woman. Arch. Mal. Coeur Vaiss 1990; 83(7):1015–8.
  42. Orti G., Mira Y., Vaya A.: Acute myocardial infarction associated with Yasmin oral contraceptive. Clin. Appl. Thromb Hemost 2007; 13(3):336–710.
  43. Benacerraf A., Veron P., Morin B. et al.: Myocardial infarction following administration of oral contraceptive agents: 3 cases. Nouv Press Med 1997; 6(1):22–6.
  44. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997; 349(9060):1202–1209.
  45. Tanis B.C., van den Bosch M.A., Kemmeren J.M. et al.: Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345(25):1787–93.
  46. Khader Y.S., Rice J., John L. et al.: Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 2003; 68(1):11–17.
  47. Baillargeon J.-P., McClish D.K., Essah P.A. et al.: Association between the Current Use of Low-Dose Oral Contraceptives and Cardiocascular Arterial Disease: A Meta-Analysis. Journal of Clinical Endocrinology & Metabolism 2005; 7:3863–3870.
  48. Spitzer W.O., Faith J.M., MacRae K.D.: Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 2002; 17:2307–14.
  49. Dunn N.R., Arscott A., Thorogood M.: The relationship between use of oral contraceptives and myocardial infarction in young women with fatal outcome, compared to those who survive: results from the MICA case-control study. Contraception 2001 Feb; 63(2):65–9.
  50. Lidegaard O., Lokkegard E., Jensen A. et al.: Thrombotic stroke and myocardial Infarction with hormonal contraception. N Engl J Med 2012; 366:2257–2266.
  51. Tanis B.C.: Oral contraceptives and the risk of myocardial infarction. Eur Heart J 2003; 24(5): 377–380.
  52. Oliveira A., Barros H., Maciel M.J. et al.: Tobacco smoking and acute myocardial infarction in young adults: a population-based case-control study. Prev Med 2007; 44(4):311–6.
  53. Dunn N.R., Faragher B., Thorogood M. et al.: Risk of myocardial infarction in young female smokers. Heart 1999 Nov; 82(5):581–3.
  54. Croft P., Hannaford P.C.: Risk factors for acute myocardial infarction in women:evidence from the Royal College of General Practitioners’ oral contraception study. BMJ 1989; 198:165–168.
  55. Rosenberg L., Palmer J.R., Rao R.S. et al.: Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001; 161(8):1065–70.
  56. Barrett D.H., Anda R.F., Escobedo L.G. et al.: Trends in oral contraceptive use and cigarette smoking. Behavioral Risk Factor Surveillance System, 1982 and 1988. Arch Fam Med 1994 May; 3(5): 438–43.
  57. Członkowska A., Ryglewicz D.: Epidemiologia udarow mozgu. Terapia 1996; 11:9–16.
  58. Kobayashi A., Niewada M., Członkowska A.: Udar mozgu – wybrane aspekty epidemiologiczne. http://www.udarmozgu.pl/dla_lekarzy/poglady_aspekty.html
  59. The World Bank. World Development Report 1993. Investing in health. Oxford University Press, Oxford 1993. Anty_druk:Layout 1 2019-02-26 12:42 Strona 76
  60. American Heart Association. Heart and stroke facts 1996 statistical supplement. American Heart Association, Dallas 1995.
  61. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; Vol 348(9026):505–10.
  62. Hannaford P.C., Croft P.R. and Kay C.R.: Oral contraception and stroke. Evidence from the Royal College of General Practitioners’ Oral Contraception Study. Stroke 1994; 25:935–942.
  1. Bushnell C.D.: Oestrogen and stroke in women: assesment of risk. Lancet Neurol 2005; 4(11): 743–51.
  2. Chasan-Taber L., Stampfer M.J.: Epidemiology of Oral Contraceptives and Cardiovascular Disease, Ann Intern Med March 15, 1998; 128:467–477.
  3. Lidegaard O., Kreiner S.: Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception 2002 Mar; 65(3):197–205.
  4. Johnston S.C., Colford Jr J.M., Gress D.R.: Oral contraceptives and the risk of subarachnoid hemorrhage. A meta-analysis. Neurology 1998; vol. 51, no. 2:411–418.
  5. Gillum L.A., Mamidipud S.K., Johnston S.C.: Ischemic Stroke Risk With Oral Contraceptives. A Meta-analysis. JAMA 2000; 284(1):72–78.
  6. Heinemann L.A., Lewis M.A., Spitzer W.O. et al.: Thromboembolic stroke in Young women. A European case-control study on oral contraceptives. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1998; 57(1):29–37.
  7. Lidegaard O.: Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ 1993; 306(6883):956–963.
  8. Poulter N.R., Chang C.L., Farley T.M. et al.: Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1999 Jul 24; 354(9175):301–2.
  9. Baillargeon J.-P., McClish D.K., Essah P.A. et al.: Association between the Current Use of Low–Dose Oral Contraceptives and Cardiocascular Arterial Disease: A Meta-Analysis. Journal of Clinical Endocrinology & Metabolism 2005; 7:3863–3870.
  10. Kemmeren J.M., Tanis B.C., van den Bosch M.A.A.J. et al.: Risk of arteria Thrombosis in relatio to Oral Contraceptives (RATIO) Study. Stroke 2002; 33:1202.
  11. Schwartz S.M., Petitti D.B. Siscovick D. et al.: Stroke and Use of Low-Dose Oral Contraceptives in Young Women. A Pooled Analysis of Two US Studies. Stroke 1998; 29:2277–2284.
  12. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996 Aug 24; 348(9026):498–505.
  13. Thorogood M., Mann J., Murphy M. et al.: Fatal Stroke and Use of Oral Contraceptives: Findings from a Case-Control Study. Am J Epidemiol 1992; 136(1):35–45.
  14. Schwartz S.M., Siscovick D., Longstreth Jr W.T. et al.: Use of Low-Dose Oral Contraceptives and Stroke in Young Women. Ann Intern Med 1997; 127:(Suppl 1):596–603.
  15. Yang L., Kuper H., Sandin S. et al.: Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stoke in a cohort study of middle-aged Swedish women. Stroke 2009 Apr; 40(4):1050–8.
  16. Siritho S., Thrift A.G., McNeil J.J. et al.: Risk of ischemic stroke among users of the oral contraceptive pill: The Melbourne Risk Factor Study (MERFS) Group. Stroke 2003 Jul; 34(7):1575–80.
  17. Mendel T.: Migrena – obecny stan wiedzy. Medycyna Rodzinna 2004; 2:50–54.
  18. Carolei A., Marini C., De Matteis G.: History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet 1996 Jun 1; 347(9014):1503–6.
  19. Schurks M., Rist P.M., Bigal M.E. et al.: Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009 Oct 27, 339:b3914. doi: 10.1136/bmj.b3914. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768778/?tool=pubmed
  20. Etminan M., Takkouche B., Isorna F.C. et al.: Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005 Jan 8; 330(7482):63.
  21. Tzourio C., Tehindrazanarivelo A., Iglesias S. et al.: Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310:830.
  22. Curtis K.M., Mohllajee A.P., Peterson H.B.: Use of combined oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review. Contraception 2006 Feb 73(2): 189–94.
  23. MacGregor E.A., Guillebaud J.: Combined oral contraceptives, migraine and ischaemic stroke. Clinical and Scientific Committee of the Faculty of Family Planning and Reproductive Health Care and the Family Planning Association. Br J Fam Plann 1998 Jul; 24(2):55–60.
  24. Chang C.L., Donaghy M., Poulter N.: Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999 Jan 2; 318(7175):13–8.
  25. Petitti D.B., Sidney S., Bernstein A. et al.: Stroke in users of low-dose oral contraceptives. N Engl J Med 1996 Jul 4; 335(1):8.
  26. Slooter A.J., Rosendaal F.R., Tanis B.C., Kemmeren J.M. et al.: Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005 Jun; 3(6):1213–7.
  27. Green D.: Thrombophilia and stroke. Top Stroke Rehabil 2003 Fall; 10(3):21–33.
  28. Zdrojewski T.: Częstość występowania i świadomość nadciśnienia tętniczego w Polsce i na świecie. Postępy Nauk Medycznych s3/2011, 4–10.
  29. Weir R.J., Briggs E., Mack A., Naismith L. et al.: Blood pressure in women taking oral contraceptives. Br Med J 1974; 1:533–535.
  30. Wilson E.S.B., Cruickshank J., McMaster M. et al.: A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen. Br J Obstet Gynaecol. Br J Obstet Gynaecol 1984; 91:1254–1260.
  31. Woods J.W.: Oral contraceptives and hypertension. Hypertension 1988 Mar; 11(3 Pt 2):II11–5.
  32. Chasan-Taber L., Willett W.C., Manson J.E. et al.: Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996 Aug 1; 94(3):483–9.
  33. Cardoso F., Polonia J., Santos A. et al.: Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet 1997 Dec; 59(3):237–43.
  34. Atthobari J., Gansevoort R.T., Visser S.T. et al.: The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate. Br J Clin Pharmacol Feb 2007; 63(2): 224–231.
  35. Lubianca J.N., Faccin C.S., Fuchs F.D.L.: Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception 2003 Jan; 67(1):19–24.
  36. Lubianca J.N., Moreira L.B., Gus M. et al.: Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens. 2005 Jun; 19(6):451–5.
  37. Khaw K.T., Peart W.S.: (Clin Res Ed). Blood pressure and contraceptive use. Br Med J 1982 Aug 7; 285(6339):403–7.
  38. Woods J.W.: Oral contraceptives and hypertension. Hypertension 1988 Mar; 11(3 Pt 2):II11–5.
  39. Kang A.K., Duncan J.A., Cattran D.C. et al.: Effect of oral contraceptives on the renin angiotensyn system and renal function. Am J Physiol Regul Integr Comp Physiol 2001 Mar; 280(3):R807–13.
  40. Ribstein J., Halimi J.M., du Cailar G. et al.: Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 1999 Jan; 33(1):90–5.
  41. Pechere-Bertschi A., Maillard M., Stalder H. et al.: Renal hemodynamic and tubular responses to salt in women using oral contraceptives. Kidney Int 2003 Oct; 64(4):1374–80.
  42. Oelkers W., Foidart J.M., Dombrovicz N. et al.: Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolizm. J Clin Endocrin Met 1995; 80(6):1816–1821.
  43. Giribela C.R., Melo N.R., Silva R.C. et al.: A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 2012 Jul; 86(1):35–41.
  44. Park H., Kim K.: Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean women. BMC Womens Health 2013 Oct 21; 13:39.
  45. Du Y., Melchert H.U., Schafer-Korting M.: Use of oral contraceptives in Germany: prevalence, determinants and use-associated health correlates. Results of National Health Surveys from 1984 to 1999. Eur J Obstet Gynecol Reprod Biol 2007 Sep; 134(1):57–66.
  46. Hickson S.S., Miles K.L., McDonnell B.J. et al.: Use of the oral contraceptive pill is associated with increased large artery stiffness in young women: the ENIGMA study. J Hypertens 2011 Jun; 29(6):1155–9.
  47. Dong W., Colhoun H.M., Poulter N.R.: Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens 1997 Oct; 15(10):1063–8.
  48. Narkiewicz K., Graniero G.R., D’Este D. et al.: Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens 1995 Mar; 8(3):249–53.